Tuesday, 27 October 2026European Markets

BORGESTAD Stock Is 9% Down So Far On Friday

Loading stream...

(VIANEWS) - Shares of BORGESTAD (Oslo Børs Benchmark Index_GI: BOR.OL) fell 9.35% to kr1.26 at 13:29 EST on Friday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is rising 0.82% to kr1,169.47, after five sequential sessions in a row of losses. This seems, up to now, a somewhat positive trend trading session today.

About BORGESTAD

Borgestad ASA develops, manufactures, distributes, and installs refractory products in Norway. The company also develops and manages real estate properties. Its properties include Agora Bytom, a shopping center with a gross area of 52,000 square meters and a rental area of approximately 30,000 square meters, as well as a parking garage with 820 parking spaces in Poland. Borgestad ASA was founded in 1904 and is headquartered in Skien, Norway.

Earnings Per Share

As for profitability, BORGESTAD has a trailing twelve months EPS of kr-13.4.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BORGESTAD's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for BORGESTAD is 141888 which is 16.93% below its average volume of 170824.

More news about BORGESTAD (BOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com